Stada expands its European treatment portfolio
Company adds a number of additional brands from Sanofi following initial take overs in 2021
Read Moreby John Pinching | Jul 12, 2023 | News | 0
Company adds a number of additional brands from Sanofi following initial take overs in 2021
Read Moreby John Pinching | Mar 7, 2023 | News | 0
Company has raised $112m in order to develop therapies for central nervous system disorders
Read Moreby John Pinching | Feb 21, 2023 | News | 0
Final draft guidance from NICE ensures people at highest risk will have access to COVID-19 therapies
Read Moreby John Pinching | Dec 7, 2022 | News | 0
Data reinforces potential to deliver new standards across HER2-targetable breast cancer
Read Moreby John Pinching | Jul 12, 2022 | News | 0
The lab will allow the Healx team to accelerate the discovery of potential new therapies for more rare conditions
Read Moreby Anna Smith | Aug 27, 2019 | News | 0
Scientists have found a way to pull down the protective wall that surrounds tumours, potentially re-exposing them to the killing power of the immune system.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
